Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Current Deferred Revenue (2016 - 2025)

Voyager Therapeutics' Current Deferred Revenue history spans 11 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 93.48% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, down 93.48%, while the annual FY2025 figure was $1.6 million, 93.48% down from the prior year.
  • Current Deferred Revenue for Q4 2025 was $1.6 million at Voyager Therapeutics, down from $10.6 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $87.0 million in Q1 2022 and bottomed at $1.6 million in Q4 2025.
  • The 5-year median for Current Deferred Revenue is $28.0 million (2023), against an average of $31.6 million.
  • The largest annual shift saw Current Deferred Revenue skyrocketed 805.62% in 2024 before it tumbled 93.48% in 2025.
  • A 5-year view of Current Deferred Revenue shows it stood at $33.9 million in 2021, then skyrocketed by 75.23% to $59.4 million in 2022, then fell by 27.78% to $42.9 million in 2023, then crashed by 43.11% to $24.4 million in 2024, then crashed by 93.48% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Current Deferred Revenue are $1.6 million (Q4 2025), $10.6 million (Q3 2025), and $20.5 million (Q2 2025).